Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
During the last decades, transplantation has become an established tool for the treatment of terminal organ failure. Beside immunological factors, hyperlipidemia is the main problem after heart transplantation, causing rapid transplant coronary artery disease (TxCAD) and poor long-term prognosis at the beginning of the transplantation. Heart transplant recipients are now effectively treated with lipid lowering substances, of which HMG-CoA-reductase inhibitors are the most potent. However, treatment with these substances correlates with an increased risk for the development of rhabdomyolysis due to therapy with the immunosuppressive cyclosporine A. Our study monitored the safety and efficacy of treatment with the HMG-CoA reductase inhibitor fluvastatin in heart transplant recipients compared to healthy controls. We investigated 10 patients receiving immunosuppressive therapy consisting of cyclosporine A, prednisone, and azathioprine who had increased concentrations of LDL-cholesterol (LDL-C), and 10 age-matched healthy controls. The patients were treated with 40 mg/day fluvastatin for 4 weeks and 20 mg/day for 4 additional weeks. Control individuals received 40 mg/day fluvastatin for 4 weeks only. Parameters of fluvastatin pharmacokinetics (maximum concentration of the drug (Cax,), time (tmax) to reach Cmax, area under the concentration vs. time curve (AUCOh 24h), elimination halflife time (t,2)), apparent total body clearance (CL), blood cyclosporine A concentration, plasma lipids, and safety parameters were determined in both study groups at the beginning of the study and after 4 weeks. The latter were determined in the patient group also after 8 and 12 weeks. Treatment with 40 mg/day fluvastatin caused a significant decrease in total cholesterol (patients: 5.47 ± 1.32 mmol/L vs. 7.30 ± 1.83 mmol/L; controls: 4.69 ± 0.64 mmolIL vs. 5.81 ± 0.72 mmol/L), LDL-C (patients: 3.28 + 1.25 mmol/L vs. 5.00 ± 1.85 mmol/L; controls: 2.58 ± 0.63 mmol/L vs. 3.50 ± 0.70 mmolJL), and triglycerides (patients: 1.99 ± 0.77 mmol/L vs. 2.50 ± 1.00 mmol/L; controls: 1.24 ± 0.46 mmolIL vs. 1.72 ± 0.67 mmol/L) in both study groups, whereas HDL-C was not significantly changed (patients: 1.29 ± 0.35 mmol/L vs. 1.17 ± 0.32 mmol/L; controls: 1.55 ± 0.30 mmol/L vs. 1.53 ± 0.26 mmol/L). Values of C,,m, and AUCOh 24h were higher in the patient group than in the control group (day 1, patients vs. controls, Cma,: 869.4 ± 604.0 ng/mL vs. 211.9 ± 113.9 ng/mL; AUCOh 24 h: 1948.8 ± 1347.9 ng/mL*h vs. 549.4 ± 247.4 ng/mLh), whereas the corresponding value of CL was lower in the patient group (33.3 ± 24.5 L/h vs. 107.9 ± 95.8 L/h), and the values of t,,,. and t,2 showed no differences. In addition, values of C,,m, and AUCOb 24h after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C,,a,: 1530.4 ± 960.4 ng/mL vs. 254.7 ± 199.8 ng/mL; AUCOb-240: 2615.3 ± 1379.4 ng/mL*h vs. 841.8 ± 421.4 ng/mL*h; CL: day 28, 21.4 ± 15.3 L/h vs. 61.5 ± 36.6 L/h). Except for an intermittent increase of creatine kinase, safety parameters showed no increases within the observation period. Our data suggest that fluvastatin effectively lowers plasma concentrations of cholesterol and LDL-C in patients after heart transplantation, however, the metabolism of fluvastatin is affected by concomitant therapy with cyclosporine A. Serum concentrations of fluvastatin should be monitored in cases of concomitant therapy with other substances interfering in the metabolism by competing cytochrome enzymes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
Lennernäs, H., & Fager, G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732050-00005 · Cited by 527 · cited 9×
“Strong differences were found in respect to physicochemical properties (molecule structure, octanol-water partitition coefficient, protein binding), dosage, number and biological activity of the metabolites, bioavailability (mechanisms of cellular uptake, tissue-selectivity, gastrointestinal absorption rate, hepatic f…”
BackgroundInfluentialWenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Steinbeck, G., Seidel, D., & Reichart, B. (1997) · Circulation · doi:10.1161/01.cir.96.5.1398 · Cited by 444 · cited 2×
“Due to the high frequency of hyperlipidemia and TxCAD, lipid lowering is an important therapeutic and preventive strategy in heart transplant patients (5-9).”
BackgroundDifferent effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
Kivistö, K. T., Kantola, T., & Neuvonen, P. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00034.x · Cited by 171
Dose Dependency of Fluvastatin Pharmacokinetics in Serum Determined by Reversed Phase HPLC
Siekmeier, R., Lattke, P., Mix, C., Park, J.-W., & Jaross, W. (2001) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840100600205 · Cited by 30
Self-citation
Cited by
Impact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 633
Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 576
Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1749-4 · Cited by 334
Metadata
- Authors
- Park, J.-W., Siekmeier, R., Lattke, P., Merz, M., Mix, C., Schuiler, S., & Jaross, W.
- Venue
- Journal of Cardiovascular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2001-12
- Volume
- 6
- Issue
- 4
- Pages
- 351-361
- ISSN
- 1074-2484 (ISSN-L)
- 1940-4034
- OpenAlex
- W2170052837
- Cited by
- 74
- References
- 5
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A. https://app.cochat.ai/papers/10.1177/107424840100600404
- The paper
- Park, J.-W., Siekmeier, R., Lattke, P., Merz, M., Mix, C., Schuiler, S., & Jaross, W. (2001). Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/107424840100600404
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.